Development Programs

Infectious Disease

Preclinical

Phase 1

Phase 2

Phase 3

Hepatitis B Prophylaxis

Sci-B-Vac®

VLP

Approved (Licensed in 10 Countries)

100%

Phase 3 (US, EU, CAN)

87%

Hepatitis B Therapeutic

VBI-2601

VLP

Preclinical

25%

Cytomegalovirus Prophylaxis

VBI-1501

eVLP

Phase 1 Complete

52%

Zika Virus Prophylaxis

VBI-2501

eVLP

Preclinical

15%

Immuno-Oncology

Preclinical

Phase 1

Phase 2

Phase 3

Glioblastoma Multiforme

VBI-1901

eVLP

Phase 1/2a

40%

Medulloblastoma

VBI-1901

eVLP

Preclinical

25%